Sepsis Fells Another Contender
Agennix's Phase II/III Study Halted by Mortality Finding
LONDON The challenging indication of severe sepsis has confounded yet another attempt to develop a registered treatment, with the curtailment of the Phase II/III trial of Agennix AG's talactoferrin.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.